Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 3/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | ANPEP | P15144 | 2/20 | 0.41 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.41 |
| ▸ | MME | P08473 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24140474 | 1.00 | SLC7A5 (0.53) | SLC7A5BLMTAAR1SLC6A2ESR1 | |
| SCHEMBL22154816 | 0.87 | ANPEP (0.41) | SLC7A5ANPEPENPEPMME | |
| SCHEMBL25831733 | 0.87 | ENPEP (0.41) | SLC7A5BLMANPEPENPEPMME | |
| SCHEMBL22154657 | 0.87 | ANPEP (0.41) | SLC7A5ANPEPENPEPMME | |
| SCHEMBL25818343 | 0.87 | ENPEP (0.41) | SLC7A5BLMANPEPENPEPMME | |
| SCHEMBL17728729 | 0.87 | EPHX1 (0.53) | SLC7A5TAAR1SLC6A2ANPEPMME | |
| SCHEMBL17728727 | 0.87 | EPHX1 (0.53) | SLC7A5TAAR1SLC6A2ANPEPMME | |
| SCHEMBL28208789 | 0.87 | EPHX1 (0.53) | SLC7A5TAAR1SLC6A2ANPEPMME | |
| SCHEMBL22121182 | 0.86 | MME (0.44) | ANPEPENPEPMMECTSSCTSK | |
| SCHEMBL22154818 | 0.86 | DPP4 (0.42) | SLC7A5ANPEPENPEPMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230414775-A1 | TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES | REGENERON PHARMACEUTICALS, INC. | 2023-12-28 | — | — | US | disclosed |
| WO-2023129518-A1 | TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES | REGENERON PHARMACEUTICALS, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230414775-A1 | TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES | SDCBP, TEK, TEKT1 | SLC7A5 1331/4885BLM 3791/4885TAAR1 2913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.